169 related articles for article (PubMed ID: 37422537)
1. CDH1 overexpression sensitizes TRAIL resistant breast cancer cells towards rhTRAIL induced apoptosis.
Tapadar P; Pal A; Ghosal N; Kumar B; Paul T; Biswas N; Pal R
Mol Biol Rep; 2023 Sep; 50(9):7283-7294. PubMed ID: 37422537
[TBL] [Abstract][Full Text] [Related]
2. ELF3 plays an important role in defining TRAIL sensitivity in breast cancer by modulating the expression of decoy receptor 2 (DCR2).
Ghosal N; Tapadar P; Biswas D; Pal R
Mol Biol Rep; 2024 May; 51(1):671. PubMed ID: 38787503
[TBL] [Abstract][Full Text] [Related]
3. Downregulation of active caspase 8 as a mechanism of acquired TRAIL resistance in mismatch repair-proficient colon carcinoma cell lines.
Van Geelen CM; Pennarun B; Ek WB; Le PT; Spierings DC; De Vries EG; De Jong S
Int J Oncol; 2010 Oct; 37(4):1031-41. PubMed ID: 20811726
[TBL] [Abstract][Full Text] [Related]
4. Repeated treatment with subtoxic doses of TRAIL induces resistance to apoptosis through its death receptors in MDA-MB-231 breast cancer cells.
Yoshida T; Zhang Y; Rivera Rosado LA; Zhang B
Mol Cancer Res; 2009 Nov; 7(11):1835-44. PubMed ID: 19843632
[TBL] [Abstract][Full Text] [Related]
5. Enhanced expression of death receptor 5 is responsible for increased cytotoxicity of theophylline in combination with recombinant human TRAIL in MDA-MB-231 breast cancer cells.
Tapadar P; Pal A; Dutta S; Pal R
J Cancer Res Ther; 2022; 18(3):754-759. PubMed ID: 35900550
[TBL] [Abstract][Full Text] [Related]
6. Identification of novel molecular regulators of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in breast cancer cells by RNAi screening.
Garimella SV; Gehlhaus K; Dine JL; Pitt JJ; Grandin M; Chakka S; Nau MM; Caplen NJ; Lipkowitz S
Breast Cancer Res; 2014 Apr; 16(2):R41. PubMed ID: 24745479
[TBL] [Abstract][Full Text] [Related]
7. The DeISGylase USP18 limits TRAIL-induced apoptosis through the regulation of TRAIL levels: Cellular levels of TRAIL influences responsiveness to TRAIL-induced apoptosis.
Manini I; Sgorbissa A; Potu H; Tomasella A; Brancolini C
Cancer Biol Ther; 2013 Dec; 14(12):1158-66. PubMed ID: 24153058
[TBL] [Abstract][Full Text] [Related]
8. Enzymatically active cathepsin D sensitizes breast carcinoma cells to TRAIL.
Jancekova B; Ondrouskova E; Knopfova L; Smarda J; Benes P
Tumour Biol; 2016 Aug; 37(8):10685-96. PubMed ID: 26867770
[TBL] [Abstract][Full Text] [Related]
9. Decreased affinity of recombinant human tumor necrosis factor-related apoptosis-inducing ligand (rhTRAIL) D269H/E195R to osteoprotegerin (OPG) overcomes TRAIL resistance mediated by the bone microenvironment.
Bosman MC; Reis CR; Schuringa JJ; Vellenga E; Quax WJ
J Biol Chem; 2014 Jan; 289(2):1071-8. PubMed ID: 24280212
[TBL] [Abstract][Full Text] [Related]
10. Modulation of TRAIL resistance in colon carcinoma cells: different contributions of DR4 and DR5.
van Geelen CM; Pennarun B; Le PT; de Vries EG; de Jong S
BMC Cancer; 2011 Jan; 11():39. PubMed ID: 21272366
[TBL] [Abstract][Full Text] [Related]
11. Sensitization of rhTRAIL-resistant Triple-negative Breast Carcinoma Through Silibinin Co-Treatment.
Manouchehri JM; Kalafatis M
Anticancer Res; 2017 Dec; 37(12):6593-6599. PubMed ID: 29187434
[TBL] [Abstract][Full Text] [Related]
12. Trailing TRAIL Resistance in Human Breast Adenocarcinoma Cells with Trichostatin A and Zebularine.
Wong SHM; Fang CM; Loh HS; Ngai SC
Anticancer Agents Med Chem; 2023; 23(7):817-831. PubMed ID: 36380402
[TBL] [Abstract][Full Text] [Related]
13. Src and ADAM-17-mediated shedding of transforming growth factor-alpha is a mechanism of acute resistance to TRAIL.
Van Schaeybroeck S; Kelly DM; Kyula J; Stokesberry S; Fennell DA; Johnston PG; Longley DB
Cancer Res; 2008 Oct; 68(20):8312-21. PubMed ID: 18922903
[TBL] [Abstract][Full Text] [Related]
14. Targeting pro-apoptotic trail receptors sensitizes HeLa cervical cancer cells to irradiation-induced apoptosis.
Maduro JH; de Vries EG; Meersma GJ; Hougardy BM; van der Zee AG; de Jong S
Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):543-52. PubMed ID: 18793956
[TBL] [Abstract][Full Text] [Related]
15. Understanding of tolerance in TRAIL-induced apoptosis and cancelation of its machinery by α-mangostin, a xanthone derivative.
Kumazaki M; Shinohara H; Taniguchi K; Ueda H; Nishi M; Ryo A; Akao Y
Oncotarget; 2015 Sep; 6(28):25828-42. PubMed ID: 26304927
[TBL] [Abstract][Full Text] [Related]
16. Smac/DIABLO enhances the therapeutic potential of chemotherapeutic drugs and irradiation, and sensitizes TRAIL-resistant breast cancer cells.
Fandy TE; Shankar S; Srivastava RK
Mol Cancer; 2008 Jun; 7():60. PubMed ID: 18590557
[TBL] [Abstract][Full Text] [Related]
17. Loss of MCL1 function sensitizes the MDA-MB-231 breast cancer cells to rh-TRAIL by increasing DR4 levels.
De Blasio A; Pratelli G; Drago-Ferrante R; Saliba C; Baldacchino S; Grech G; Tesoriere G; Scerri C; Vento R; Di Fiore R
J Cell Physiol; 2019 Aug; 234(10):18432-18447. PubMed ID: 30912136
[TBL] [Abstract][Full Text] [Related]
18. Involvement of DR4/JNK pathway-mediated autophagy in acquired TRAIL resistance in HepG2 cells.
Lim SC; Jeon HJ; Kee KH; Lee MJ; Hong R; Han SI
Int J Oncol; 2016 Nov; 49(5):1983-1990. PubMed ID: 27665736
[TBL] [Abstract][Full Text] [Related]
19. Drug-induced caspase 8 upregulation sensitises cisplatin-resistant ovarian carcinoma cells to rhTRAIL-induced apoptosis.
Duiker EW; Meijer A; van der Bilt AR; Meersma GJ; Kooi N; van der Zee AG; de Vries EG; de Jong S
Br J Cancer; 2011 Apr; 104(8):1278-87. PubMed ID: 21487429
[TBL] [Abstract][Full Text] [Related]
20. MiR-126 reverses drug resistance to TRAIL through inhibiting the expression of c-FLIP in cervical cancer.
Zhang W; Zhou J; Zhu X; Yuan H
Gene; 2017 Sep; 627():420-427. PubMed ID: 28669929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
